These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 20357795)

  • 1. Trial watch: Phase III success for novel Clostridium difficile antibiotic.
    Nat Rev Drug Discov; 2010 Apr; 9(4):260. PubMed ID: 20357795
    [No Abstract]   [Full Text] [Related]  

  • 2. Fidaxomicin: a macrocyclic antibiotic for the management of Clostridium difficile infection.
    Sullivan KM; Spooner LM
    Ann Pharmacother; 2010 Feb; 44(2):352-9. PubMed ID: 20071495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic.
    Johnson AP
    Curr Opin Investig Drugs; 2007 Feb; 8(2):168-73. PubMed ID: 17328233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection.
    Louie TJ; Emery J; Krulicki W; Byrne B; Mah M
    Antimicrob Agents Chemother; 2009 Jan; 53(1):261-3. PubMed ID: 18955523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection.
    Venugopal AA; Johnson S
    Clin Infect Dis; 2012 Feb; 54(4):568-74. PubMed ID: 22156854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of RBx 11760, a novel biaryl oxazolidinone, against Clostridium difficile.
    Mathur T; Kumar M; Barman TK; Kumar GR; Kalia V; Singhal S; Raj VS; Upadhyay DJ; Das B; Bhatnagar PK
    J Antimicrob Chemother; 2011 May; 66(5):1087-95. PubMed ID: 21393140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Refractory Clostridium difficile infection. Untraditional treatment of antibiotic-induced colitis].
    Fløtterød O; Hopen G
    Tidsskr Nor Laegeforen; 1991 Apr; 111(11):1364-5. PubMed ID: 2042156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection.
    Louie T; Miller M; Donskey C; Mullane K; Goldstein EJ
    Antimicrob Agents Chemother; 2009 Jan; 53(1):223-8. PubMed ID: 18955525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fidaxomicin: a minimally absorbed macrocyclic antibiotic for the treatment of Clostridium difficile infections.
    Soriano MM; Liao S; Danziger LH
    Expert Rev Anti Infect Ther; 2013 Aug; 11(8):767-76. PubMed ID: 23977933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A case of slowly resolving enteritis caused by Clostridium difficile].
    Zoppi G; Vinco A; Cinquetti M; Barbato G; Luciano A
    Pediatr Med Chir; 1995; 17(5):459-60. PubMed ID: 8685005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of fidaxomicin for Clostridium difficile treatment.
    Simon MS
    Clin Infect Dis; 2014 Feb; 58(4):603. PubMed ID: 24300043
    [No Abstract]   [Full Text] [Related]  

  • 12. Fidaxomicin: a macrocyclic antibiotic for the treatment of Clostridium difficile infection.
    Hardesty JS; Juang P
    Pharmacotherapy; 2011 Sep; 31(9):877-86. PubMed ID: 21923589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical inquiries. What are effective therapies for Clostridium difficile-associated diarrhea?
    Ohl ME; Stevermer JJ; Meadows S; Tribuna J; Chek K
    J Fam Pract; 2005 Feb; 54(2):176-8. PubMed ID: 15689297
    [No Abstract]   [Full Text] [Related]  

  • 14. Vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea.
    Bishara J; Wattad M; Paul M
    Clin Infect Dis; 2007 Dec; 45(12):1646-7; author reply 1649-51. PubMed ID: 18190329
    [No Abstract]   [Full Text] [Related]  

  • 15. Vancomycin therapy for severe Clostridium difficile-associated diarrhea.
    Huggan PJ; Murdoch DR
    Clin Infect Dis; 2007 Dec; 45(12):1647-8; author reply 1649-51. PubMed ID: 18190330
    [No Abstract]   [Full Text] [Related]  

  • 16. Fidaxomicin failures in recurrent Clostridium difficile infection: a problem of timing.
    Orenstein R
    Clin Infect Dis; 2012 Aug; 55(4):613-4. PubMed ID: 22610922
    [No Abstract]   [Full Text] [Related]  

  • 17. Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection.
    Citron DM; Babakhani F; Goldstein EJ; Nagaro K; Sambol S; Sears P; Shue YK; Gerding DN
    Anaerobe; 2009 Dec; 15(6):234-6. PubMed ID: 19755166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clostridium difficile-associated disease treatment response depends on definition of cure.
    Lawrence SJ; Dubberke ER; Johnson S; Gerding DN
    Clin Infect Dis; 2007 Dec; 45(12):1648; author reply 1649-51. PubMed ID: 18190331
    [No Abstract]   [Full Text] [Related]  

  • 19. Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study.
    Garey KW; Jiang ZD; Bellard A; Dupont HL
    J Clin Gastroenterol; 2009 Jan; 43(1):91-3. PubMed ID: 18385603
    [No Abstract]   [Full Text] [Related]  

  • 20. Acyldepsipeptide antibiotics as a potential therapeutic agent against Clostridium difficile recurrent infections.
    Gil F; Paredes-Sabja D
    Future Microbiol; 2016 Sep; 11():1179-89. PubMed ID: 27546386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.